Inhibition of TUG1 could become a promising strategy to restore antitumor immunity by regulating PD‐L1 and CD47, which could provide new ideas for designing effective immunotherapeutic strategies and improve the therapeutic effect of current immune checkpoint inhibitors for HCC. Here, TUG1 is linked to hepatocellular carcinoma.